These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37731262)

  • 1. Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series.
    Idowu M; Garcia RL; Sule OB
    J Investig Med High Impact Case Rep; 2023; 11():23247096231191873. PubMed ID: 37731262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy.
    Broderick GA
    J Sex Med; 2012 Jan; 9(1):88-103. PubMed ID: 21699659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
    Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
    Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential efficacy of crizanlizumab in treating priapism in sickle cell disease: A case report.
    Abdulgayoom M; Afana MS; Alshurafa A; Yassin MA
    Clin Case Rep; 2024 May; 12(5):e8585. PubMed ID: 38736574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Men with sickle cell disease experience greater sexual dysfunction when compared with men without sickle cell disease.
    Idris IM; Abba A; Galadanci JA; Mashi SA; Hussaini N; Gumel SA; Burnett AL; DeBaun MR
    Blood Adv; 2020 Jul; 4(14):3277-3283. PubMed ID: 32702096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priapism and Sickle Cell Disease: Special Considerations in Etiology, Management, and Prevention.
    Ahuja G; Ibecheozor C; Okorie NC; Jain AJ; Coleman PW; Metwalli AR; Tonkin JB
    Urology; 2021 Oct; 156():e40-e47. PubMed ID: 34181970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
    Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
    N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizanlizumab: First Approval.
    Blair HA
    Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multisystem damage associated with tricorporal priapism in sickle cell disease.
    Sharpsteen JR; Powars D; Johnson C; Rogers ZR; Williams WD; Posch RJ
    Am J Med; 1993 Mar; 94(3):289-95. PubMed ID: 8452153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
    Kanter J; Ataga KI; Bhasin N; Guarino S; Kutlar A; Lanzkron S; Manwani D; McGann P; Stowell SR; Tubman VN; Yermilov I; Campos C; Broder MS
    Ann Hematol; 2024 Jun; 103(6):1909-1917. PubMed ID: 38642304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
    Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
    Sy SKB; Tanaka C; Grosch K
    Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating stuttering priapism.
    Kheirandish P; Chinegwundoh F; Kulkarni S
    BJU Int; 2011 Oct; 108(7):1068-72. PubMed ID: 21914108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of priapism in sickle-cell diseases with alpha-adrenergic agonists].
    Gbadoé AD; Koffi KS; Akakpo-Maxwell O; Lawson-Evi K; Guédéhoussou T; Assimadi JK
    Sante; 2002; 12(3):343-7. PubMed ID: 12473531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experience of patients with sickle cell disease treated with crizanlizumab.
    Chan KH; Buddharaju R; Idowu M
    J Investig Med; 2024 Feb; 72(2):242-247. PubMed ID: 38073007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial--the priapism in sickle cell study.
    Olujohungbe AB; Adeyoju A; Yardumian A; Akinyanju O; Morris J; Westerdale N; Akenova Y; Kehinde MO; Anie K; Howard J; Brooks A; Davis VA; Khoriatry AI
    J Androl; 2011; 32(4):375-82. PubMed ID: 21127308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat priapism.
    Anele UA; Le BV; Resar LM; Burnett AL
    Blood; 2015 Jun; 125(23):3551-8. PubMed ID: 25810489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
    Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA
    Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.